Technology Behind Gemelli Biotech’s Trio-Smart® Used in New Study Linking Intestinal Sulfide Overproduction to a Distinct Small-Bowel Gene-Expression Signature

Technology Behind Gemelli Biotech’s Trio-Smart® Used in New Study Linking Intestinal Sulfide Overproduction to a Distinct Small-Bowel Gene-Expression Signature




Technology Behind Gemelli Biotech’s Trio-Smart® Used in New Study Linking Intestinal Sulfide Overproduction to a Distinct Small-Bowel Gene-Expression Signature

Exploratory research in mSystems finds broader small-bowel gene-expression changes in ISO than in methanogen overgrowth or culture-defined bacterial overgrowth, with each condition showing a distinct profile, supporting the biological rationale for distinguishing them




MESA, Ariz.–(BUSINESS WIRE)–A new peer-reviewed study in mSystems, a journal of the American Society for Microbiology, finds that intestinal sulfide overproduction (ISO) is associated with a distinct gene-expression signature in the small bowel, one that looks markedly different from two related conditions commonly grouped with ISO.

ISO, small intestinal bacterial overgrowth (SIBO), and intestinal methanogen overgrowth (IMO) are microbial imbalances closely tied to irritable bowel syndrome (IBS), which affects an estimated 6.1% of U.S. adults yet remains widely underdiagnosed. In this study, researchers classified ISO and IMO from fasting breath samples, measuring hydrogen sulfide and methane, respectively, and classified SIBO using duodenal aspirate culture. Until now, no study had compared how gene activity in patients’ own intestinal cells differs across the three conditions.

Led by researchers at the MAST Program at Cedars-Sinai, with breath gases measured using proprietary gas chromatography by Gemelli Biotech, the study analyzed small-bowel biopsies from 85 participants undergoing upper gastrointestinal endoscopy, measuring which genes were more or less active in their intestinal cells.

The findings point to three biologically distinct conditions. Among patients who had only one of the three, no differentially expressed gene was shared across all three groups, and pairwise overlap was minimal. ISO, associated with elevated hydrogen sulfide, showed by far the broadest changes, involving genes associated with energy production, oxidative balance, immune signaling, and intestinal fluid regulation and transit, a pattern with potential relevance to mechanisms associated with diarrhea-predominant IBS. IMO and SIBO were associated with substantially fewer gene-expression changes in this group. In animal experiments, rats exposed to some hydrogen-sulfide-producing bacteria showed partially concordant changes, while a non-producing strain did not show the same broad ISO-associated pattern.

Because their symptoms overlap, the three conditions can be hard to tell apart clinically. The study suggests that treating them as biologically interchangeable may overlook meaningful differences. The study’s breath measurements were performed using Gemelli Biotech’s gas chromatography technology, the same technology that enables its Trio-Smart breath test to detect hydrogen sulfide. For Gemelli, the findings add peer-reviewed support to the scientific rationale for distinguishing these conditions.

The physician-led research team concluded that the study “supports the need for individualized therapeutic strategies for each condition in the future.”

Ritesh Agarwal, chief executive officer of Gemelli Biotech, said: “For years, patients with elevated hydrogen sulfide could receive breath-test results that appeared normal or incomplete because conventional tests did not directly measure all three gases. This research reinforces that ISO has a biologically distinct profile. Trio-Smart is currently the only clinical breath test in the U.S. that measures hydrogen, methane, and hydrogen sulfide, giving patients and clinicians a more complete picture of intestinal gas production and the conditions associated with it.”

About Gemelli Biotech: Gemelli Biotech develops precision laboratory tests that identify measurable imbalances in key biological markers of gut health, available with the convenience of at-home collection. Its core diagnostics are Trio-Smart®, the only at-home breath test that measures all three fermentation gases associated with microbial overgrowth (hydrogen, methane, and hydrogen sulfide) in a single test, and IBS-Smart®, the only licensed, clinically validated blood test for post-infectious IBS, which measures two validated antibody biomarkers (anti-CdtB and anti-vinculin). Developed in partnership with the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai and grounded in peer-reviewed gastrointestinal research, including work referenced in ACG and AGA clinical guidelines, Gemelli’s tests are processed in a centralized CLIA-certified laboratory and are available by physician order and patient-directed access across all 50 U.S. states and territories, with more than 100,000 patients and providers served to date.

For more information, visit triosmartbreath.com

Disclosure: Cedars-Sinai has a licensing agreement with Gemelli Biotech. Study authors Ali Rezaie, MD, Mark Pimentel, MD, and Ruchi Mathur, MD, hold equity in Gemelli Biotech.

Additional author disclosures are available in the published article.

Reference: de Freitas Germano J, Leite G, Villanueva-Millan MJ, et al. Transcriptomics profiles in intestinal sulfide overproduction, small intestinal bacterial overgrowth, and intestinal methanogen overgrowth. mSystems. Published online June 29, 2026. https://journals.asm.org/doi/10.1128/msystems.00458-26

Contacts

Media Contact: ContactUs@gemellibiotech.com

Darwin Biotech Presented Randomized Phase 1 ALS Study Data of Cell-Free ALT001 and U.S. Phase 1/2 Study Design at 2026 NEALS Annual Meeting

Darwin Biotech Presented Randomized Phase 1 ALS Study Data of Cell-Free ALT001 and U.S. Phase 1/2 Study Design at 2026 NEALS Annual Meeting




Darwin Biotech Presented Randomized Phase 1 ALS Study Data of Cell-Free ALT001 and U.S. Phase 1/2 Study Design at 2026 NEALS Annual Meeting

  • ALT001 was well tolerated in randomized Phase 1 ALS study, with early signals on Function and NfL
  • No treatment-related serious adverse events at any of three doses
  • ALS function scores and plasma neurofilament light chain favored ALT001 over placebo at Day 31
  • U.S. Phase 1/2a study planned to test higher doses

BEIJING & CLEARWATER, Fla.–(BUSINESS WIRE)–Darwin Biotech (“Darwin”), a clinical-stage company developing treatments for neurological diseases, today announced that data from its randomized, double-blind, placebo-controlled Phase 1 study of ALT001 in amyotrophic lateral sclerosis (ALS), including 12-week results from an ongoing open-label extension (OLE), were presented in a poster at the 2026 Network of Excellence for ALS (NEALS) Annual Meeting, taking place October 27-30 in Clearwater, Florida.


ALT001 is a novel, cell-free protein complex derived from human mesenchymal stem cells. The Phase 1 study, led by Principal Investigator Prof. Yilong Wang and team at Beijing Tiantan Hospital, Capital Medical University, enrolled 36 participants with ALS who were randomized 3:1 to ALT001 at 1.0, 2.0 or 4.0 μg/kg or placebo (27 ALT001; 9 placebo). Primary endpoints were safety, tolerability, maximum tolerated dose and recommended dose. Secondary endpoints included the ALS Functional Rating Scale–Revised (ALSFRS-R), the ALS Assessment Questionnaire-40 (ALSAQ-40), the Modified Norris Scale, forced vital capacity, muscle function and biomarkers including plasma neurofilament light chain (NfL).

Key Phase 1 findings include:

  • Safety: ALT001 was generally well tolerated across all dose levels, with no treatment-related serious adverse events (SAEs) or significant intolerance events (SIEs) reported and no dose-limiting toxicities identified.
  • ALSFRS-R: At Day 31, mean ALSFRS-R scores increased from baseline by 1.22, 0.78 and 0.44 points in the 1.0, 2.0 and 4.0 μg/kg groups, respectively, compared with a mean decline of 0.78 points with placebo.
  • Plasma NfL: At Day 31, mean plasma NfL decreased from baseline by 5.02%, 17.16% and 17.05% in the 1.0, 2.0 and 4.0 μg/kg groups, respectively, compared with 2.23% with placebo.
  • Other measures: ALSAQ-40 scores showed favorable trends, Modified Norris Scale scores were generally stable, and grip strength was better preserved at 1.0 and 2.0 μg/kg than with placebo.

Efficacy measures were secondary endpoints, and these results are preliminary given the study’s size and 31-day treatment period.

Following the Phase 1 study, 29 of 36 participants entered a 12-week OLE (11, 8 and 10 participants in the 1.0, 2.0 and 4.0 μg/kg cohorts, respectively), in which participants originally assigned to placebo received ALT001 at their cohort’s dose. Among participants originally treated with ALT001, mean ALSFRS-R change from OLE baseline to Week 12 was −1.5, −3.4 and −1.3 points in the 1.0, 2.0 and 4.0 μg/kg cohorts, respectively. ALSFRS-R trajectories suggested slower functional decline in OLE participants than in Phase 1 participants who did not enter the extension. These findings are exploratory and are based on small, non-randomized groups with different follow-up timelines.

“ALT001 was well tolerated at every dose we tested,” said Weiqi Chen, M.D., Ph.D., Associate Chief Physician and Associate Professor, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, presenting on behalf of Lead Principal Investigator Prof. Yilong Wang. “Over the month of treatment, patients on ALT001 held their function and saw their NfL levels come down, while patients on placebo declined. These are encouraging early results, and I look forward to studying ALT001 in larger trials.”

Darwin plans to further evaluate ALT001 in a seamless adaptive U.S. Phase 1/2a study. Part A is an open-label dose-escalation phase evaluating 1.0, 3.0 and 9.0 μg/kg in sequential cohorts of three to six participants to identify the recommended Phase 2 dose (RP2D). In Part B, 12 participants will be randomized 3:1 to ALT001 or placebo in a double-blind, placebo-controlled evaluation for up to 24 weeks. Primary endpoints are safety and tolerability, including RP2D selection; secondary endpoints include change from baseline in ALSFRS-R and plasma NfL.

“These results give us a clear path forward for ALT001 globally,” said Wang Yu, Founder and Chief Executive Officer of Darwin. “We are grateful to the patients, their caregivers and doctors at Beijing Tiantan Hospital who made this study possible. We are now planning a Phase 1/2a study in the U.S. that will test higher doses against placebo over a longer period. Our team at the NEALS Annual Meeting has been holding conversations with some of the most prominent U.S. members of the ALS medical community and we look forward to advancing our clinical program in the United States as well.”

Dr. Chen presented the poster on behalf of Principal Investigator Prof. Yilong Wang, titled “Darwin-ALT001 for Amyotrophic Lateral Sclerosis (ALS): Results from a Randomized Phase I Study and Open-Label Extension in China, and Design of a U.S. Phase I/IIa Study,” on Thursday, October 29, 2026, between 4:50 pm – 6:30 pm ET during Poster Session 2 (poster 208).

About ALT001

ALT001 is a novel, independently developed biologic. Its active component is a protein complex derived from the secretome of human umbilical cord-derived mesenchymal stem cells. The therapy is currently in clinical development for neurological conditions, including ALS and ischemic stroke, with ongoing research into its pharmacokinetics, biomarkers, and commercial-scale manufacturing.

About ALS

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease, is a rare and fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons in the brain and spinal cord. This leads to muscle weakness, atrophy, and eventually paralysis, typically resulting in death within 3-5 years of symptom onset due to respiratory failure. The global incidence of ALS is approximately 1.5-2.5 per 100,000 people per year, with a prevalence of about 4-6 per 100,000. While ALS can affect individuals of any age, it most commonly presents between the ages of 40 and 70. The disease affects both upper and lower motor neurons, leading to a combination of spasticity, hyperreflexia, muscle weakness, fasciculations, and atrophy. The lack of effective treatments highlights the urgent need for novel therapeutic approaches that can address the complex, multi-factorial pathophysiology of ALS.

About Darwin

Darwin Biotechnology is a clinical-stage biotechnology company that has developed a proprietary, first-of-its-kind platform for mesenchymal stem cell (MSC)-derived protein complexes, together with supporting manufacturing processes and quality control and release systems. Guided by Quality by Design (QbD) principles, the platform enables the development of cell-free, non-exosomal protein complex biologics derived from MSCs. It is designed to preserve the coordinated biological activity of multiple cell-derived proteins while improving manufacturing consistency, product stability, and control over scale-up, laying the foundation for lower production costs and broader patient access. In neurology, Darwin prioritizes serious central nervous system (CNS) and other neurological disorders, with lead clinical programs in amyotrophic lateral sclerosis (ALS) and ischemic stroke. These programs are evaluating the therapeutic potential of targeting multiple disease mechanisms to promote neuroprotection and functional recovery. Darwin integrates basic research, clinical translation, and global regulatory strategy while building its commercial manufacturing infrastructure. The company aims to bring quality-assured, affordable cell-free protein complex therapeutics to patients worldwide. Through collaborations with medical institutions and research teams in China and internationally, Darwin continues to investigate mechanisms of action, generate clinical evidence, and advance the clinical development and application of this innovative technology.

Forward-Looking Statements & Cautionary Note

This document contains forward-looking statements, including projections regarding future revenues, product development timelines, and market expansion. These statements are based on current expectations, estimates, and assumptions that are subject to risks and uncertainties.

Actual results may differ materially from those projected due to factors including, but not limited to, changes in general economic conditions, loss of key personnel, delays in technology or product rollouts, intense market competition, and the company’s ability to secure additional capital. Recipients and prospective investors are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances occurring after the date of this document

Contacts

ICR Healthcare (Media & Investor Relations)


Media Relations

Sean Leous

Senior Vice President

Sean.Leous@ICRHealthcare.com

Investor Relations

Stephanie Carrington

Managing Director

Stephanie.Carrington@ICRHealthcare.com

Gerresheimer Reports Revenue Growth and Stable Adjusted EBITDA in the Third Quarter of 2026 

Gerresheimer AG

/ Key word(s): Quarter Results/9 Month figures

Gerresheimer Reports Revenue Growth and Stable Adjusted EBITDA in the Third Quarter of 2026 

30.10.2026 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Gerresheimer Reports Revenue Growth and Stable Adjusted EBITDA in the Third Quarter of 2026 

  • Preliminary Q3 Results: Revenue EUR 605 million; adjusted EBITDA EUR 103 million
  • Preliminary 9M Results: Revenue EUR 1.7 billion; adjusted EBITDA EUR 272 million
  • Stronger Q4 2026 expected in line with guidance
  • Preparations for the completion of the PPP sale

Duesseldorf, October 30, 2026. Gerresheimer, an innovative systems and solutions provider and global partner to the pharma, biotech, and cosmetics industries, today released preliminary results for the third quarter of 2026 and the first nine months of financial year 2026. Revenue, including the business units currently in the sales process, rose by 8% year-over-year to EUR 605 million in the third quarter of 2026 (Q3 2025: EUR 560 million, adjusted). Adjusted EBITDA reached EUR 103 million (Q3 2025: EUR 106 million, adjusted), remaining stable at the same level as in the previous year’s quarter. In the first nine months of the financial year, revenue, based on preliminary figures, was approximately at the previous year’s level at EUR 1.7 billion (9M 2025: EUR 1.7 billion, adjusted). Adjusted EBITDA, at EUR 272 million (9M 2025: EUR 331 million, adjusted), fell short of the previous year’s period due to inventory reductions and weaker performance in the Tubular Glass Europe and Moulded Glass business. With an adjusted EBITDA margin of 17.1% in the third quarter of 2026 (Q3 2025: 19.0%, adjusted), the adjusted EBITDA margin for the first nine months totaled 15.9% (9M 2025: 19.4%, adjusted). Revenue performance in the third quarter and the first nine months of 2026 was positively influenced primarily by the Containment & Delivery Systems division, driven by higher demand for drug delivery devices. Looking ahead to the remainder of financial year 2026, Gerresheimer expects a stronger fourth quarter with further earnings improvement, in line with its guidance. Following the successful completion of the Centor sale, Gerresheimer is now moving forward with the completion of the sale of the Primary Packaging Plastics business (PPP). The closing preparations are progressing well. As a result, the transaction is currently expected to close already in the first quarter of 2027.    

“Revenue growth in the third quarter of 2026, stable adjusted EBITDA compared to the same quarter last year, and a substantial improvement in our financial situation resulting from the successful completion of the Centor sale in October demonstrate the progress of our transformation,” said Wolf Lehmann, CFO of Gerresheimer AG. “The next milestones will be the closing of the sale of the Primary Packaging Plastics business and a comprehensive refinancing.” 

Containment & Delivery Systems: Drug Delivery Devices Drive Growth
The Containment & Delivery Systems division increased revenue and earnings in both the third quarter and the first nine months of 2026. According to preliminary figures and including the business units currently in the sales process, revenue in the first nine months of 2026 totaled approximately 917 million EUR (9M 2025: 876 million EUR, adjusted), of which the third quarter of 2026 contributed approximately 313 million EUR (Q3 2025: EUR 286 million, adjusted). Adjusted EBITDA rose to EUR 211 million in the first nine months of 2026 (9M 2025: EUR 194 million, adjusted), with the third quarter of 2026 contributing approximately EUR 77 million (Q3 2025: EUR 64 million, adjusted). The adjusted EBITDA margin was 23.9% in the first nine months (9M 2025: 22.2%, adjusted). The adjusted EBITDA margin of 24.5% in the third quarter (Q3 2025: 22.3%) contributed substantially to this improvement. The division benefited from rising demand for drug delivery devices. In recent years, Gerresheimer had invested in expanding production capacity in this division. The ramp-up of production is now leading to increasing revenue and earnings contributions.

Primary Injectable Solutions: Business stabilized in Q3
According to preliminary figures, the Primary Injectable Solutions division generated revenues of EUR 335 million in the first nine months of 2026 (9M 2025: EUR 360 million, adjusted), of which EUR 123 million was generated in the third quarter of 2026 (Q3 2025: EUR 114 million, adjusted). Adjusted EBITDA amounted to EUR 32 million (9M 2025: EUR 69 million, adjusted), of which the division generated EUR 15 million in the third quarter of 2026 (Q3 2025: EUR 19 million, adjusted). The adjusted EBITDA margin for the first nine months of 2026 totaled 9.5% due to the significantly weaker first half of the year (9M 2025: 19.3%, adjusted). Here, too, the third quarter of 2026, with an adjusted EBITDA margin of 12.5% (Q3 2025: 16.8%, adjusted) demonstrated the stabilization of the business, even though revenue, earnings, and the adjusted EBITDA margin for the first nine months were collectively below the previous year’s period. As part of the transformation program, measures are currently underway to improve capacity utilization and competitiveness in the Tubular Glass business.

Moulded Glass: Revenue stabilized in Q3; earnings impacted by inventory reduction
According to preliminary figures, the Moulded Glass division generated revenues of EUR 479 million in the first nine months of 2026 (9M 2025: EUR 492 million, adjusted), of which EUR 169 million was generated in the third quarter of 2026 (Q3 2025: EUR 165 million, adjusted). Adjusted EBITDA amounted to EUR 52 million (9M 2025: EUR 91 million, adjusted), of which the division generated EUR 17 million in the third quarter of 2026 (Q3 2025: EUR 29 million, adjusted). The adjusted EBITDA margin totaled 10.9% in the first nine months of 2026 (9M 2025: 18.6%, adjusted), whereby the adjusted EBITDA margin in the third quarter at 10.2% (Q3 2025: 17.4%, adjusted) was below the overall margin. In a weaker market environment, the Moulded Glass division reported lower revenue. In addition, inventory levels were reduced as part of cash management initiatives, which further lowered capacity utilization and had a negative impact on adjusted EBITDA. In this division as well, Gerresheimer has initiated measures to improve performance as part of its transformation program. For example, the Moulded Glass plant in Chicago Heights, USA, was closed in September 2026. 

Gerresheimer expects to publish its Q3 Quarterly Statement, containing the final figures for the third quarter and the first nine months of financial year 2026, in December 2026.

About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. The Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com

 

Contact Gerresheimer

Media  
Jutta Lorberg
Group Senior Director
Communication & Marketing
T +49 211 6181 264
jutta.lorberg@gerresheimer.com
Dersim Korkmaz
Manager Corporate Communication
T +49 211 6181 296
dersim.korkmaz@gerresheimer.com
 
Investor Relations
 
Guido Pickert
Vice President Investor Relations
T +49 211 6181 220
gerresheimer.ir@gerresheimer.com
 


30.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Gerresheimer AG
Peter-Müller-Str. 3
40468 Duesseldorf
Germany
Phone: +49-(0)211/61 81-00
Fax: +49-(0)211/61 81-121
E-mail: gerresheimer.ir@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 5299006GD4UWSYZOKC28
EQS News ID: 2424748

 
End of News EQS News Service

2424748  30.10.2026 CET/CEST

PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category

PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category




PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category

Recognition highlights PureTech’s differentiated model for identifying and advancing medicines through the creation of dedicated biotechnology companies

BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that it has won the 2026 Prix Galien USA Award for “Incubators, Accelerators and Equity.” The award was presented at the 20th Annual Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City. PureTech was honored for its model of identifying and de-risking therapeutic candidates and establishing dedicated companies to advance the most promising programs toward patients.




PureTech’s approach is grounded in its LIFE (Launching Innovation From Existing Pharmacology) model, a systematic framework for identifying opportunities to unlock the potential of validated pharmacology, with a hub-and-spoke structure designed to advance those opportunities efficiently. As programs reach key value-inflection points, PureTech launches dedicated Founded Entities with their own leadership teams and attracts third-party investment to advance them. PureTech’s approach has delivered an 80% clinical trial success rate and three FDA-approved therapeutics. Complementing this track record of clinical success, PureTech’s hub-and-spoke model has enabled the creation of dedicated Founded Entities that have attracted more than $4 billion in third-party financing since 2018.

“We are honored to receive this recognition from the Galien Foundation, which is a testament to the vision and dedication of our team over more than two decades,” said Robert Lyne, Chief Executive Officer of PureTech. “Our model was built on the belief that promising science deserves a path forward, even when traditional development approaches fall short. By combining our ability to unlock the potential of validated pharmacology with a model that brings together dedicated teams and external capital, we have created a portfolio spanning FDA-approved medicines, publicly traded companies, and early-stage programs. We are proud of what this approach has achieved and remain focused on translating innovative science into medicines that make a meaningful difference for patients.”

About The Galien Foundation

The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Today, the Prix Galien operates through 18 chapters spanning more than 75 countries across Africa, the Americas, Asia, and Europe. Expansion is currently underway in China, Singapore, and Australia.

In 2025, the Foundation launched the inaugural Prix Galien Bridges Forum and Awards Ceremony at the Nobel Forum in Stockholm, spanning Northern and Southern Europe, Israel, and the Middle East, and the first-ever Patient Summit for Prix Galien USA, reinforcing its commitment to science without borders.

The Nobel Prize and the Prix Galien share a common birthplace in Paris, where Alfred Nobel signed his last will and testament in 1895. However, while the Nobel Prize in Physiology or Medicine recognizes up to three individuals for specific discoveries, the Prix Galien honors the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media: Facebook | X | LinkedIn

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Contacts

PureTech
Public Relations

publicrelations@puretechhealth.com
Investor Relations

IR@puretechhealth.com

AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG continues its growth in the third quarter of 2026, driven by higher average room rates and strong activity at its flagship properties

AEVIS VICTORIA SA

/ Key word(s): 9 Month figures

AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG continues its growth in the third quarter of 2026, driven by higher average room rates and strong activity at its flagship properties

30.10.2026 / 07:00 CET/CEST


Press release

Interlaken, 30 October 2026

AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG continues its growth in the third quarter of 2026, driven by higher average room rates and strong activity at its flagship properties

MRH Switzerland AG, the hotel division of AEVIS VICTORIA SA, continued to grow over the first nine months of 2026. Revenue reached CHF 159.5 million, an increase of 1.3% compared to the same period in 2025. The third quarter confirmed the resilience of business activity, with particularly strong acceleration in September.

As of 30 September 2026, accommodation revenue increased by 1.8% to CHF 95.7 million. The average daily room rate rose by 5.4% to CHF 607, while revenue per available room (RevPAR) increased by 5.1% to CHF 348. The occupancy rate remained stable at 57.4%.

This performance confirms MRH Switzerland’s ability to capitalise on its upscale offering and pursue its strategy of qualitative growth, prioritising improvements in average room rates and revenue per available room.

Particularly positive momentum in the third quarter
This trend was particularly pronounced in September, with revenue of CHF 16.3 million, up 9.2% compared to September 2025. The average daily room rate reached CHF 488, an increase of 17.9%, while RevPAR rose by 14.3% to CHF 295.

Several flagship properties contributed to this momentum. The Victoria-Jungfrau Grand Hotel & Spa in Interlaken recorded revenue of CHF 43.9 million over the first nine months, up 3.5%, with a 6.6% increase in the average daily room rate. La Réserve Eden au Lac Zurich reported revenue growth of 4.4%, while AlpenGold Hotel Davos achieved an increase of 10.1%.

Outlook
Following a significant investment cycle across its properties, MRH Switzerland continues its strategy of enhancing the value of its hotel portfolio, building on the quality of its assets, their positioning in leading destinations and the expertise of Michel Reybier Hospitality.

For more information:
Media and investor relations: c/o Dynamics Group, Zurich
Marion Schihin, msc@dynamicsgroup.ch, + 41 79 705 88 15

About MRH Switzerland AG
MRH Switzerland AG is a hotel chain operating eleven hotels in Switzerland and abroad, under the Michel Reybier Hospitality brand. The hotels are located in premium destinations, including Zurich, Interlaken, Bern, Crans Montana, Zermatt, Davos, Flims and London. MRH Switzerland AG manages a portfolio with 1’180 rooms in operation, generating substantial annual traffic with 367’819 overnight stays. The chain employs 1’153 staff members. MRH Switzerland AG is a 100% subsidiary of AEVIS VICTORIA SA. www.michelreybierhospitality.com

About Michel Reybier Hospitality
For more than 20 years, Michel Reybier has been blazing the trail for a singular, highly contemporary vision of luxury and hospitality. Each of the Michel Reybier Hospitality destinations upholds his cherished values of excellence, authenticity and simplicity. Whether in a hotel, a villa or a private apartment, in the mountains or by the sea, in the countryside, in the heart of the vineyards or in the city… A sole requirement: namely exceptional places that throb with a distinctive emotion. A sole ambition: to share a refined art of living, dedicated above all else to our guests’ well-being and pleasure. This holistic approach is based on unforgettable experiences, where sport, food, wellness and passion form an inseparable whole. This approach is supported by the medical expertise of Nescens, whose ultimate goal is to ensure people live better, healthier lives for as long as possible. The promise of instilling meaning into each and every moment. www.michelreybierhospitality.com

About AEVIS VICTORIA SA
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS’s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (22.6%, directly and indirectly), a listed real estate company (INFRAC.SW) dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com


End of Media Release


2424870  30.10.2026 CET/CEST

Chinese medical AI model wins top state science award as sectoral “ChatGPT moment” arrives

EQS Newswire / 30/10/2026 / 12:35 UTC+8

Results have recently been released for the final of the National Healthcare Security AI Image Recognition Contest. The contest, organised by China’s National Healthcare Security Administration, was built around real-world clinical imaging requirements. A total of 1,332 teams across China participated. Drawing on Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS)’s proprietary iMedImage®, the world’s first cross-modal foundation model, and its iMedLoop™ medical imaging AI R&D and production acceleration platform, a team from the Second Affiliated Hospital of Guangxi University of Chinese Medicine developed a CT diagnostic model for kidney cancer to claim first prize in the contest, while a breast cancer X-ray diagnostic model built by the First Affiliated Hospital of Guangxi Medical University secured second prize.

These remarkable results further validate DIAGENS’ technological leadership in the global medical AI sector and the broad applicability of its solutions.

In China, clinicians have taken center stage in the field of medical AI, with a domestic foundational technology stack enabling cross-modal applications to claim top awards. DIAGENS translated sophisticated R&D capabilities into foundations and tooling accessible to clinical teams, enabling clinicians to evolve from AI end-users into AI creators. The “ChatGPT moment” for medical imaging has arrived.

 

Foundation model: resetting the starting point for AI-driven medical innovation

Clinical specialists understand disease pathology best and grasp most clearly the pain points to resolve in real-world clinical workflows. For years, technical barriers spanning data processing, algorithm development, model training, evaluation and deployment have prevented vast pools of clinical expertise from translating directly into AI systems.

DIAGENS has rewritten this R&D pathway. Founded in 2016, the Hong Kong-listed artificial intelligence firm is recognised as the world’s first publicly listed company focused on medical imaging foundation models. It specialises in artificial intelligence and biomedicine, and aims to build a global industrialization platform for medical imaging AI. Centered on its self-developed iMedImage® medical imaging foundation model, the company provides a shared development backbone for specialised disease models. With 104 billion parameters, the model was pre-trained on 80 million clinical imaging studies. It delivers multi-modal compatibility across CT, X-ray, MRI, and ultrasound. Model support was available across 26 clinical specialties and over 4,000 disease scenarios. New clinical tasks can be adapted atop this existing foundation, reducing redundant effort associated with development from scratch.

On this basis, DIAGENS links data generation, model training, unified evaluation, deployment and application feedback via its iMedLoop™ medical imaging AI R&D and production acceleration platform, forming an integrated closed-loop R&D and production pipeline. Powered by iMedImage® and iMedLoop™, clinicians define tasks, set benchmarks and participate in development around real clinical challenges. The mature foundation and platform provide the capacity to tackle intricate technical and engineering challenges.

This framework packages DIAGENS’ long-accumulated technical expertise into an accessible platform, returns control of innovation to clinical teams, and supports disease specialists in leading innovation in medical AI.

 

National contest validation: proving the industrial rollout pathway for medical AI

The strong performance of the kidney cancer CT-based and mammography X-ray detection projects led by frontline clinicians at this contest stands as real-world proof of DIAGENS’ multimodal foundation capabilities and industrial innovation framework, demonstrated on a national professional stage.

Beyond the contest, this underlying technology stack has already undergone scaled rollout across clinical practice. Built on the iMedImage® medical imaging foundation model, DIAGENS has extended the capability frontier of medical imaging AI across diverse imaging modalities. CT, X-ray, MRI and ultrasound, alongside karyotyping and cytomorphology studies, all draw on the same foundational backbone and R&D-to-production pipeline. To date, DIAGENS has delivered a cumulative total of 158 model projects in partnership with 99 hospitals — 65 of which are Grade III Class A hospitals — spanning 43 anatomical sites and 61 disease categories.

This unified underlying capability spans multiple imaging modalities to support an ongoing stream of distinct diseases and clinical tasks. The industrialized framework enables batch development of high-performance specialist AI tools. DIAGENS continues to roll out its leading capabilities across further niche medical imaging verticals.

 

China’s new approach: ushering in the “ChatGPT moment” for global medical AI

ChatGPT redefined how people interact with AI, unlocking access to powerful AI capabilities for broader user groups. DIAGENS is reshaping how medical AI is developed. Its foundation model and R&D platform cut development hurdles for specialty-specific models, enabling more clinical specialists to shift from AI end-users to AI creators.

When clinicians can build AI models without writing code themselves, the scope for clinical innovation broadens substantially. Clinicians across diverse specialties can pursue research around their own clinical challenges, test hypotheses, translate specialist experience into a rich ecosystem of AI models, and distil clinical wisdom into reusable, deployable medical AI capabilities. This technical pathway rooted in Chinese practice widens the community of medical AI builders and expands the pool of beneficiaries of these innovations.

Powering multi-modal innovation, this industrial framework delivers on the “one foundation for thousands of models” paradigm — marking the arrival of the “ChatGPT moment” in medical imaging. DIAGENS leverages its homegrown proprietary technology to lead a global shift in the production of medical imaging AI.

 

30/10/2026 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results

Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results




Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results

  • Revenue increased 19.7% to 1.167 trillion yen year-over-year driven by Enhertu® and Datroway®
  • Fiscal year 2026 guidance for revenue and operating profit remains unchanged
  • Earnings call to take place on Friday, October 30 at 5:30 pm Japan Standard Time

TOKYO–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026.


“Strong revenue growth continues in the second quarter of fiscal year 2026, driven by Enhertu and Datroway. These medicines have received nine new approvals across multiple indications since last quarter, including same day breast cancer approvals in Japan and China, which will allow us to bring these medicines to more patients,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “We also continue to explore novel combination strategies to deliver greater benefits to more patients through our DXd antibody drug conjugates as demonstrated by our new clinical trial collaboration to evaluate Datroway with ivonescimab.”

Q2 FY2026 Results

Global revenue increased 19.7% year-over-year to 1.167 trillion yen, driven by the company’s global oncology medicines. Operating profit increased 34.4% year-over-year to 193.8 billion yen.

Global revenue was driven by Enhertu® and Datroway®, the company’s two lead antibody drug conjugates (ADCs). Enhertu revenue, including milestone payments, was 500.0 billion yen, a 51.4% increase year-over-year. Datroway revenue, including milestone payments, was 54.4 billion yen, a 161.6% increase year-over-year.

Revenue from the Oncology Business in the U.S., Europe and Canada was 422.6 billion yen, a year-over-year increase of 54.8%, with revenue driven by Enhertu and Datroway. Japan Business was 232.7 billion yen, a year-over-year decrease of 6.9%, with revenue driven by Lixiana®, Tarlige®, Enhertu and Pralia®. ASCA (Asia, South and Central America) Business revenue was 142.5 billion yen, a 20.9% year-over-year increase, driven by Enhertu. European Union (EU) Specialty Business revenue was 149.2 billion yen, a 9.1% year-over-year increase, driven by Lixiana and Nilemdo®/Nustendi®.

Full fiscal year 2026 guidance remains unchanged. Global revenue is anticipated to reach 2.34 trillion yen with an operating profit of 320.0 billion yen.

Further details on financial performance can be found in the Financial Results Presentation Material. Daiichi Sankyo will host an investor and media conference call and webcast to discuss Q2 FY2026 results on Friday, October 30 at 5:30 pm Japan Standard Time.

Q2 FY2026 and Recent Portfolio / Pipeline Highlights

Daiichi Sankyo continued to advance its portfolio and pipeline with several milestones across its oncology portfolio, demonstrating momentum towards its goal of launching 20 new indications across five medicines by 2030.

Eight additional breast cancer approvals for Enhertu and Datroway were received in China, the EU and Japan since Q1 FY2026. These approvals included Enhertu in combination with pertuzumab for the first-line treatment of patients with HER2 positive metastatic breast cancer based on DESTINY-Breast09 and Datroway for the first-line treatment of patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy based on TROPION-Breast02. Additional approvals of Enhertu in the adjuvant setting of HER2 positive early breast cancer based on DESTINY-Breast05 were received in China and the EU.

Enhertu also was approved for a tumor agnostic indication in China based on four phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02 and DESTINY-PanTumor03.

Data from DESTINY-Lung04 were presented during Presidential Symposium 2 at the IASLC 2026 World Conference on Lung Cancer, which showed Enhertu demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a first-line treatment of patients with unresectable, locally advanced or metastatic HER2 mutant non-squamous non-small cell lung cancer (NSCLC). The results will be shared with global regulatory authorities for a potential new indication for Enhertu in this lung cancer setting.

The Biologics License Application seeking accelerated approval in the U.S. for ifinatamab deruxtecan (I-DXd) for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) was voluntarily withdrawn. Patient enrollment is near completion in the IDeate-Lung02 phase 3 trial, where these results may support the potential global submissions of ifinatamab deruxtecan for relapsed ES-SCLC.

Daiichi Sankyo and AstraZeneca entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. to evaluate Datroway in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin the collaboration with a phase 3 trial in first-line TNBC. Separately, the TROPION-Urothelial04 phase 3 trial evaluating Datroway as an adjuvant combination treatment in patients with muscle invasive urothelial cancer was initiated.

Medicine

Indication

Q2 FY2026 and Recent Portfolio Updates

Enhertu

Breast

  • Enhertu Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer (October 2026)
  • Enhertu Approved in China as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer (October 2026)
  • Enhertu and Datroway Approved in Japan for Two New First-Line Indications for Patients with Metastatic Breast Cancer (September 2026)
  • Enhertu Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer (September 2026)
  • Enhertu Plus Pertuzumab Approved in China as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer (August 2026)

Lung

  • Enhertu Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial (September 2026)

Tumor Agnostic

  • Enhertu Approved in China as First and Only Tumor Agnostic HER2 Directed Medicine and Antibody Drug Conjugate for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors (October 2026)

 

Datroway

Breast and Lung

  • Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway in Combination with Ivonescimab Across Multiple Tumor Types (October 2026)

Breast

  • Datroway Approved in China as First and Only TROP2 Directed Antibody Drug Conjugate with Overall Survival Benefit for Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for PD 1/PD-L1 Inhibitor Therapy (October 2026)
  • Enhertu and Datroway Approved in Japan for Two New First-Line Indications for Patients with Metastatic Breast Cancer (September 2026)
  • Datroway Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy (July 2026)

Datroway

Urothelial

  • TROPION-Urothelial04 Phase 3 Trial of Datroway Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer (August 2026)

 

I-DXd

Lung

  • Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn (September 2026)

 

Corporate Highlights

Daiichi Sankyo appointed Ken Keller to the newly created role of Chief Commercialization Officer effective April 1, 2027, where he will be responsible for accelerating further growth of the company’s oncology and specialty medicine business through a new globally integrated Commercialization Unit.

Daiichi Sankyo received a favorable judgment from the Tokyo District Court dismissing all damage claims filed by Northern TK Venture (NTK).

About Daiichi Sankyo

Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to being a trusted healthcare innovator, contributing to the enrichment of quality of life around the world through its strengths in science and technology. At Daiichi Sankyo, we believe progress depends on asking more of science, challenging assumptions and pursuing better answers. Progress like this is built by people who never stop learning, questioning and pushing what’s possible. Together, we work to bring new breakthrough medicines within reach for patients and help shape what comes next in oncology and beyond. For more information, please visit www.daiichisankyo.com and connect with us on LinkedIn.

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements, including words such as “advance,” “anticipate,” “favorable,” “goal,” “momentum,” and “progress” were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from the outlook of Daiichi Sankyo or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantees that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. This material disclosed here is for reference purposes only.

Final investment decisions should be made at your own discretion. Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

Contacts

MEDIA CONTACTS:
Global:
Jennifer Brennan

jennifer.brennan@daiichisankyo.com
+1 908 900 3183 (mobile)

INVESTOR RELATIONS CONTACT:

DaiichiSankyoIR_jp@daiichisankyo.com

Japan:

DS-PR_jp@daiichisankyo.com

Monsanto unanimously wins first Roundup™ trial since U.S. Supreme Court decision

Monsanto unanimously wins first Roundup™ trial since U.S. Supreme Court decision




Monsanto unanimously wins first Roundup™ trial since U.S. Supreme Court decision

Missouri verdict demonstrates that plaintiffs could not prove their claims following the U.S. Supreme Court’s landmark decision in Durnell

ST. LOUIS–(BUSINESS WIRE)–A Missouri Circuit Court jury today reached a unanimous defense verdict in favor of Monsanto in the three-plaintiff case of Theresa Aretino, et al. v. Monsanto Company, the first Roundup™ trial to take place since the U.S. Supreme Court’s landmark ruling in Monsanto v. Durnell. The jury found for Monsanto on the design defect, fraud and negligence claims that each of the three plaintiffs pursued at trial following the Supreme Court’s favorable decision in Durnell, which preempted their failure-to-warn claims.

“We are pleased with the jury’s favorable verdict for Monsanto validating our belief that there is no evidence to prove design defect, fraud or negligence claims in the Roundup™ litigation,” said Bill Dodero, U.S. General Counsel and Global Head of Litigation. “This verdict should send a strong signal that plaintiffs who wish to pursue claims in the court system following the Durnell ruling will face significant challenges both in demonstrating they have viable claims and putting forth the necessary evidence to prove them in court.”

The first trial following Durnell

In June 2026, the U.S. Supreme Court issued a landmark ruling in the Durnell Roundup™ case, affirming that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state law claims based on failure-to-warn theories when the Environmental Protection Agency (EPA) has made a definitive determination on product safety. These claims have been a central theory in the Roundup™ litigation to date. With failure-to-warn claims no longer available, the Aretino plaintiffs pursued design defect and negligence claims. The verdict marks the first time a court has tested the sufficiency of evidence to support design defect and negligence claims at trial in the post-Durnell landscape.

Glyphosate’s safety

Glyphosate remains one of the most studied agricultural tools in history. The overwhelming weight of scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide support the safety of glyphosate-based herbicides when used as directed. The U.S. EPA has repeatedly and unequivocally determined that glyphosate is not likely to be carcinogenic and has consistently approved Roundup™ labels that contain no cancer warnings.

The company will continue to back the safety of its glyphosate-based herbicides – critical tools that farmers rely on to produce affordable food and feed the world – and will vigorously defend its products in any remaining litigation.

Find more information at www.bayer.com.

pb (2026-0183E)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

Contacts

Contact for media inquiries:
Brian Leake, phone +1 314.370.3285
Email: brian.leake@bayer.com

Philipp Blank, phone +49 214 30-20499
Email: philipp.blank@bayer.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com
www.bayer.com/en/investors/ir-team

Contact for U.S. investor inquiries:
Erica Mulligan, phone +1 314-985-7457
Email: erica.mulligan@bayer.com

University Eye Center Los Angeles and Walgreens Offer Free Flu Shots for Uninsured and Underinsured LA Residents This November

University Eye Center Los Angeles and Walgreens Offer Free Flu Shots for Uninsured and Underinsured LA Residents This November




University Eye Center Los Angeles and Walgreens Offer Free Flu Shots for Uninsured and Underinsured LA Residents This November

Walk-in Clinics at University Eye Center Los Angeles on Nov. 3, 17 and 19 Help Residents Get Protected Before Flu Season Peaks and Holiday Gatherings Begin

LOS ANGELES–(BUSINESS WIRE)–The University Eye Center Los Angeles, part of Ketchum Health, the clinical teaching facility of Marshall B. Ketchum University (MBKU), is partnering with Walgreens to offer free flu shots to uninsured and underinsured Los Angeles residents at three clinics this November, giving patients time to build protection before the holidays.




The clinics are aimed at the Angelenos most likely to go without a flu shot. About 1 in 12 Los Angeles County residents had no health insurance in 2024, according to the latest U.S. Census Bureau data, and the California Health Care Foundation expects that number to climb as Medi-Cal enrollment declines. Many others have coverage but still face high out-of-pocket costs or long waits for an appointment.

And going without a flu shot carries real risk. During last year’s flu season, the Centers for Disease Control and Prevention (CDC) estimated at least 32 million flu illnesses, 390,000 hospitalizations and 24,000 deaths nationwide.

Hosting the clinics at the University Eye Center Los Angeles puts free shots in a neighborhood clinic that residents already know and trust. MBKU educates the next generation of optometrists, physician assistants and pharmacists. It also offers advanced degrees in vision science and medical science. Its interdisciplinary approach trains students from each program to work side by side, and the flu clinics bring that team-based model to the community MBKU serves in Los Angeles.

“For many families we see at Ketchum Health, a flu shot is easy to put off when money is tight or a doctor’s appointment is weeks away, and that delay can mean missed work, missed school or a hospital visit that didn’t need to happen,” said Lisa Wahl, OD, clinic director at University Eye Center Los Angeles. “Offering free, walk-in flu shots right here in the neighborhood takes those barriers away. Working with Walgreens lets us reach more people before the worst of flu season hits.”

Walgreens pharmacists, assisted by MBKU students, will give the shots, which are funded through Walgreens vouchers, so the trivalent flu vaccine is free to eligible patients with no insurance needed. Patients with insurance who want other vaccines, such as COVID-19, at the same visit can request them, and pharmacists will process those claims on site.

Clinic dates:

  • Tuesday, Nov. 3, 10 a.m.-1 p.m.
  • Tuesday, Nov. 17, 10 a.m.-1 p.m.
  • Thursday, Nov. 19, 10 a.m.-1 p.m.

The CDC recommends an annual flu vaccine for everyone six months and older, and the vaccine takes about two weeks to build full protection. Patients vaccinated Nov. 3 will be protected by Thanksgiving, and those who come Nov. 17 or 19 will be protected ahead of December holiday gatherings. Walk-ins and appointments are both welcome.

All three clinics take place at the University Eye Center Los Angeles located at 3916 S. Broadway, Los Angeles, CA 90037. To schedule an appointment, call 323.234.9137.

About Marshall B. Ketchum University: Marshall B. Ketchum University (MBKU) is an independent, private, non-profit, accredited educational institution located in Fullerton, California proudly preparing the health care leaders of the future through immersive and rigorous academic programs that teach, train and graduate tomorrow’s clinical experts. Established in 1904, more than 100 years later, MBKU today includes four primary schools: 1) Southern California College of Optometry which offers a Doctor of Optometry and a Master of Science in Vision Science degree; 2) its School of Physician Assistant Studies which awards a Master of Medical Science degree; 3) its College of Pharmacy, that offers a Doctor of Pharmacy degree; and 4) its Doctor of Medical Science program, which provides a Doctor of Medical Science degree. With a nationally recognized faculty known for offering the highest level of expertise and experience in clinical education and training; a commitment to introducing students to the latest in technology, diagnosis and treatment; as well as small class sizes and a tight-knit family feel—MBKU graduates become part of a diverse and inclusive alumni group that includes some of the health care industry’s most accomplished researchers, clinicians and teachers. MBKU also provides personalized care to the communities it serves from two state-of-the-art optometry clinics offering comprehensive vision care for all ages, from infants to seniors. Its wide array of services include cornea and contact lenses, pediatric vision, ocular disease treatment and consultation, vision therapy, low vision and more. More services can be found online at the University Eye Center at Ketchum Health Anaheim and University Eye Center at Ketchum Health Los Angeles. Accessible primary care medical services are also available at its Ketchum Health Medical Clinic. To learn more about MBKU’s programs or public clinics, visit https://www.ketchum.edu/ or follow on Facebook, Instagram and LinkedIn.

Editor’s Note: Spokespeople will be available for on-site interviews at all three clinics. To attend as press or schedule an interview, contact ketchum@beyondfifteen.com or 949.733.8679.

Contacts

MEDIA CONTACT: Beyond Fifteen Communications, Inc.

ketchum@beyondfifteen.com | 949.733.8679

Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026

Issuer: Immunic AG

/ Key word(s): Conference

Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026

29.10.2026 / 11:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day
on November 5, 2026

NEW YORK, October 29, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET.

In addition to members of Immunic’s management team, including Erik Lundgren, M.B.A., Chief Executive Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer, Hella Kohlhof, Ph.D., Chief Scientific Officer, and Jason Tardio, M.B.A., President & Chief Operating Officer, the event will feature presentations by two renowned experts in the treatment of MS and development of new therapies, Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University of Toronto, and Maria Pia Sormani, Ph.D., University of Genoa, Italy.

The group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression. Immunic management will highlight the potential expansion opportunity for lead investigational asset vidofludimus calcium (IMU-838) in progressive MS, including the clinical and scientific rationale supporting Immunic’s plans to initiate a Phase 3 progressive MS trial later in 2026. The differentiated profile of vidofludimus calcium, including its activity as a nuclear receptor-related 1 (Nurr1) activator and the potential neuroprotective effects associated with this mechanism, provides scientific rationale for its evaluation in progressive forms of MS.

The Virtual Progressive MS R&D Day will take place on Thursday, November 5, 2026, at 12:30 pm ET. To register for the event, please CLICK HERE.
 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is expected later in 2026. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
 

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

 

US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com

 

US Media Contact
Real Chemistry
media@imux.com


Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.